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Background: One of the problems with burn patients is the impairment of host immunity, which makes difficult to treat. In burns, immunoglobulin 
A has demonstrated to decrease. Immunoglobulin A is the main product of mucous immune system, which increases viral clearance and decreases 
bacterial adhesion in the intestine. Probiotics consist of living microflora, which control the balance of lactobacilli and bifidobacteria in the intestine. 
Instead of producing organic component, increasing the acidity of intestine, mucin and bacteriocin, they also activate the intestinal immune system 
and secretory immunoglobulin A (sIgA). The goal of this study was to propose that regular intake of probiotic might help to improve the mucous 
immune system, especially sIgA in intestines in burn patients.
Methods: An experimental, double-blind, controlled clinical trial was carried out in 33 burn patients. Those patients were divided into two groups. 
The first group was given daily probiotic and the second group was given only placebo for 10 days. The treatment began on the 4th day admission, and 
then, the degree of sIgA was evaluated before treatment and day 14 from fecal specimen.
Results: Significant differences between probiotic and control group were observed (p<0.0001). The degree of sIgA in the probiotic group increased 
61.25%, and in the control group, it decreased to 36.80%.
Conclusion: The mucous immune system, especially sIgA, increases by probiotic intake.
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INTRODUCTION
Burns will activate a local inflammatory reaction that develops into a 
systemic reaction by releasing toxins associated with immunologic 
processes of the body, as a lipoprotein complex (lipid–protein complex, 
burn toxin) which induces the Systemic Inflammatory Response 
Syndrome (SIRS) event. Detection of SIRS symptoms and bacteremia 
are an element for diagnosing sepsis. Some previous studies have noted 
that the incidence of bacteremia in burns patients is about to occur on 
the 6th to the 10th day after trauma [1,2]. Burn wound infection is the 
highest incidence of the onset of sepsis compared with other trauma. 
Because gastrointestinal damage will occur due to splanchnic hypoxia 
resulting bacteria translocation.
Burn victims’ statistical data number in 2000 are 7-8 million people, 
with a mortality rate of 70.000-80.000 and 500.000-800.000 need of 
require treatment. In Europe, 2–2.5 million casualties were reported, 
with death from 20,000 to 25,000 [3,5]. The incidents of burn victims at 
Dr. Soetomo Hospital in 2007-2008 are 33 patients with IIAB grade and 
>20% of burn, as much as 64% occured in bacteremia as seen in Table 1.
Some literature has been shown that bacteria may penetrate the 
intestinal wall through the lymph channels leading to regional lymph 
nodes and into the bloodstream. The role of the bacteria translocation 
on human is not clearly known. It has been demonstrated that the 
complication of severe infection is generally caused by Pseudomonas, 
Staphylococcus coagulase-negative bacteria, Candida and Enterococcus. 
All of these bacteria/fungus is a bacteria which live in the bowel of 
sepsis patients [4,6,7].
Probiotics are dietary supplements containing life microflora that 
may be consumed in sufficient measure to provide benefits for the 
host health. Some mechanisms have been known including regulate 
the balance of lactobacili and bifidobacteria from intestinal flora 
by producing organic component, which increase the acidity of the 
intestinal flora resulting inhibit the growth of various harmfull bacteria, 
mucin and bacteriocin which acts as a natural antibiotics. This activity 
plays a role in the immune response by increasing the number of 
lymphocytes, macrophages and normal cell killer, producing cytokines, 
Interleukin (IL)-12, IL-10, tumor necrosis factor alpha, interferon 
gamma and secreting immunoglobulin A (IgA) [8-10].
Currently, probiotics are not only consumed as a drug but also 
processed as an additive in food products (food additive) or milk 
and are consumed every day by healthy or sick individuals. However, 
research is mainly carried out by dairy food producers and more 
focused on safety when they are consumed in the long term by healthy 
individuals, and not much about the effectiveness or the immune 
response was generated by its hosts. Numerous animal studies 
mention that probiotics may influence the host immune response 
by increasing the production of secretory immunoglobulin mainly 
secretory IgA (sIgA) [11,12].
Burns trigger an increase of permeability of the intestinal wall because 
of reperfusion result in increasing the risk of bacteria translocation 
and endotoxemia and histological lesions in the mucosa and 
decreasing levels of IgA immunoglobulin and mucin. Administration 
of Bifidobacteria preparations may reduce the ratio of the balance of 
aerobic bacteria and endotoxemia and mucosal lesions and reduce 
symptoms of digestive disorders such as diarrhea in patients with 
burns [13-15]. By administering the probiotic preparations will obtain 
the increased levels of intestinal sIgA significantly in the mice [16,17]. 
A clear mechanism of how probiotics may enhance the mucosal immune 
response is disputed and needs further research [18].
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METHODS
To meet the experimental research design, patients were randomized 
and divided in the probiotic and placebo group in a double-blind manner. 
Researchers gave probiotic to the treatment group and placebo to the 
control group. In this study, we obtained 34 samples, with 17 samples 
for each group, but the treatment group had one dropout.
It is a double-blind clinical trial pre-test–post-test control group 
experimental research that was conducted to prove the effect of 
probiotics on the levels of stool sIgA in patients with burns.
The ratio data in the research variables such as age, extensive burns, 
and sIgA underwent a normality test using Kolmogorov–Smirnov test 
of one sample prior to statistics analysis. The test results showed that 
all of these variables were within normal distribution, so the statistical 
analysis will use parametric test group.
Homogeneity test for age, sex, and extent of burns was performed on 
both the groups to explore whether all study subjects were at the same 
condition at the beginning of the study.
RESULTS AND DISCUSSION
Fig. 1 shows about sIgA levels in healthy person and in burn patients 
with probiotic and without probiotic taken from day 4. In Fig. 2 shows 
about sIgA levels in burn patients given probiotic and without probiotic 
taken on day 10.
The mean levels of sIgA in the group given probiotic were lower than 
the group not given probiotic. Results of statistical analysis using two 
independent samples t-test are p=0.014 >α 0.05, means there is a 
significant difference in the means of sIgA in both groups.
A difference in the mean of sIgA level in the group given probiotic 
increased 61.25%, while in the group not given probiotic decreased 
36.80%. The results of statistical analysis two independent samples 
t-test are p<0.0001; it implies that there is a significant difference 
on difference of sIgA levels between day 4 and 10 in the two groups 
(Table 2).
DISCUSSION
Double-blind clinical trial experimental study with pre-test–post-
test control group had been done to study the effect of probiotics’ 
administration to the level of fecal sIgA in patients with burns. In this 
study, there were 34 samples with 17 samples in each group, but in the 
treatment group, there was one patient dropout. The study subjects 
were matched with the inclusion and exclusion criteria. It had been 
statistically analyzed that the subject distribution of age, sex, and the 
extent of the burns were normal, so it could be said the subjects were 
homogen.
The mean level of sIgA in burns’ patient in day 4 was 0.240 mg/g, slightly 
lower than the level of sIgA in a healthy subject (mean: 0.317 mg/g) 
(Table 1). In severe burns, there was a decrease of IgA, IgG, IgN, and IgE 
level which occurred in days 2–3 after the trauma. However, from the 
t-test result of two free samples, p=0.138 or more than α 0.05, which 
means there was no significant difference in the mean of sIgA between 
the two groups.
Table 2 shows that the mean sIgA was increased in group given 
probiotics in day 4 with a mean of 0.175 mg/g and in day 10 with a 
mean of 0.259 mg/g. The result of statistical analysis using paired t-test 
showed that there was a significant difference (p<0.0001). In the group 
which was not given probiotics, the mean sIgA was 0.301 mg/g in day 4, 
and in day 10, it decreased to 0.170 mg/g (p=0.004).
To compare the change of sIgA level between day 4 and 10 in groups 
given probiotics and not given probiotics, the difference between 
sIgA levels was used. The difference of sIgA level in the group given 
probiotics was decreased to 36.80%. Statistical analysis using t-test 
in two free samples showed p<0.0001, which showed that there was 
a significant difference between sIgA levels in days 4 and 10 in the two 
groups (Table 2).
CONCLUSION
This study used probiotics latent product which consists of mixed 
bacteria with the composition of Lactobacillus bulgaricus, Bifidobacteria 
brave, Bifidobacterium longum, and Streptococcus thermophilus which 
were Gram-positive bacteria. Those materials had been chosen as 
treatment regimen because those products consisted of probiotic 
bacteria strains which had been tested in many studies for their benefit 
as mucosal immunomodulator [19-21]. By using multistrain probiotics, 
a synergic modulation effect was expected. In this study, probiotic 
strain which had more roles in increasing immunoglobulin synthesis 
was not known. Ideally, study using some single strains had to be done, 
so it could prove which probiotic strain that had more roles. The reason 
of the product usage is because this product could be easily found in 
the market. The probiotic mechanism to increase intestinal sIgA level 
which was represented by fecal examination in this study was not done. 
Fig. 1: Chart of secretory immunoglobulin A levels in healthy 
person, probiotic, without probiotic
Fig. 2: Chart of secretory immunoglobulin A levels in burn 
patients given probiotic and without probiotic on day 10
Table 1: Incident of burns>20% grade IIAB at RSUD Dr. Soetomo





Table 2: Changes in the sIgA levels (mg/g) between day 4 











Mean 0.084 (61.25) −0.131 (−36.80) <0.0001
SD 0.061 (53.48) 0.162 (20.98)
Minimum 0.001 (0.64) −0.728 (−76.23)
Maximum 0.188 (168.25) −0.002 (−1.41)
SD: Standard deviation, sIgA: Secretory immunoglobulin A
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However, some literatures suggested that peptidoglycan in the cell wall 
of the probiotic bacteria would play a role as an antigen in intestinal 
lumen which stimulate intestinal mucosal immune response [22,23].
By the increase of the level of sIgA after probiotics’ administration in 
patients with burns, it was expected that the intestinal immunity system 
would increase; thus, bacterial translocation would be reduced. The 
mortality and morbidity level of burns’ patients would also reduce [24].
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